Wednesday - June 3, 2026
FDA Center for Biologics Evaluation & Research Issues Warning Letter to Blue Horizon International
June 03, 2026
WASHINGTON, June 3 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Blue Horizon International LLC from its Center for Biologics Evaluation and Research:

* * *

Recipient: Dr. Brian Mehling, Chief Medical Officer and Founder, Blue Horizon International, LLC, 214 State Street Suite 101, Hackensack, NJ 07601, United States, bmehling@bluehorizoninternational.com

Issuing Office: Center for B . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products